I-Chow Joe Hsu, MD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
I-Chow Joe Hsu, MD

Associate Professor, Department of Radiation Oncology, UCSF

Phone: (415) 353-9807 (appts, new), 353-9894 (appts, follow-up)
Box 0226, UCSF
San Francisco, CA 94143-0226

View on UCSF Profiles

Cancer Center Membership

Associate Member ┬╗ Prostate Cancer

Education

University of Florida, Gainesville, FL, BS, 1983-87, Biochemistry
Johns Hopkins School of Med., Baltimore, MD, MD, 1987-91, Medicine
San Bernardino County Med. Ctr., SB, CA, 1991-92, Internship
Columbia-Presbyterian Med. Ctr., NY, NY, 1992-95, Residency


Professional Experience

  • 1995-1997
    Attending Physician, Radiation Oncology, California Endocurietherapy Cancer Center, Oakland CA
  • 1997-1998
    Clinical Assistant Professor, Department of Radiation Oncology, University of California San Francisco
  • 1998-2004
    Assistant Professor of Clinical Radiation Oncology, Department of Radiation Oncology, University of California, San Francisco
  • 2004-present
    Associate Professor of Clinical Radiation Oncology, Department of Radiation Oncology, University of California, San Francisco

Honors & Awards

  • 1987
    Alpha Epsilon Delta Medical Honor Society
  • 1987
    University of Florida, BS, Magna cum Laude
  • 1988, 1990
    Dean's Fund for Research, Johns Hopkins School of Medicine
  • 1989
    The John Scott McFarland Fund, Johns Hopkins School of Medicine
  • 1991
    Accolade for Outstanding Intern, San Bernardino County Hospital

Selected Publications

  1. Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer. Radiat Oncol. 2016; 11(1):8.
    View on PubMed
  2. Patient- and treatment-specific predictors of genitourinary function after high-dose-rate monotherapy for favorable prostate cancer. Brachytherapy. 2015 Jul 18.
    View on PubMed
  3. Inverse Planned High-Dose-Rate Brachytherapy for Locoregionally Advanced Cervical Cancer: 4-Year Outcomes. Int J Radiat Oncol Biol Phys. 2015 Aug 1; 92(5):1093-100.
    View on PubMed
  4. Postoperative radiation therapy for patients at high-risk of recurrence after radical prostatectomy: does timing matter? BJU Int. 2015 Nov; 116(5):713-20.
    View on PubMed
  5. Dose-volume analysis and the temporal nature of toxicity with stereotactic body radiation therapy for prostate cancer. Pract Radiat Oncol. 2015 Sep-Oct; 5(5):e465-72.
    View on PubMed
  6. Evaluation of PC-ISO for Customized, 3D Printed, Gynecologic 192-Ir HDR Brachytherapy Applicators. J Appl Clin Med Phys. 2015; 16(1):5168.
    View on PubMed
  7. Bladder wall recurrence of prostate cancer after high-dose-rate brachytherapy. Brachytherapy. 2015 Mar-Apr; 14(2):185-8.
    View on PubMed
  8. ACR appropriateness Criteria® Postradical prostatectomy irradiation in prostate cancer. Oncology (Williston Park). 2014 Dec; 28(12):1125-30, 1132-6.
    View on PubMed
  9. Two phase I dose-escalation/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with local regionally recurrent breast cancer. Int J Hyperthermia. 2014 Aug; 30(5):285-94.
    View on PubMed
  10. Pre-plan parameters predict post-implant D90 = 140 Gy for (125)I permanent prostate implants. J Contemp Brachytherapy. 2014 Jun; 6(2):143-53.
    View on PubMed
  11. ACR Appropriateness Criteria® Definitive External-Beam Irradiation in stage T1 and T2 prostate cancer. Am J Clin Oncol. 2014 Jun; 37(3):278-88.
    View on PubMed
  12. Response to Drs Rogers, Hayes, and Demanes. Brachytherapy. 2014 Sep-Oct; 13(5):523-5.
    View on PubMed
  13. Quality improvement of International Classification of Diseases, 9th revision, diagnosis coding in radiation oncology: Single-institution prospective study at University of California, San Francisco. Pract Radiat Oncol. 2015 Jan-Feb; 5(1):e45-51.
    View on PubMed
  14. Model-based feasibility assessment and evaluation of prostate hyperthermia with a commercial MR-guided endorectal HIFU ablation array. Med Phys. 2014 Mar; 41(3):033301.
    View on PubMed
  15. A training phantom for ultrasound-guided needle insertion and suturing. Brachytherapy. 2014 Jul-Aug; 13(4):413-9.
    View on PubMed
  16. A review of safety, quality management, and practice guidelines for high-dose-rate brachytherapy: executive summary. Pract Radiat Oncol. 2014 Mar-Apr; 4(2):65-70.
    View on PubMed
  17. Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir. Radiat Oncol. 2014; 9:42.
    View on PubMed
  18. Long-term Outcomes Following Radiation Therapy For Prostate Cancer Patients With Lymph Node Metastases at Diagnosis Treated With and Without Surgery. Am J Clin Oncol. 2014 Jan 16.
    View on PubMed
  19. Dosimetric Analysis of Radiation Therapy Oncology Group 0321: The Importance of Urethral Dose. Practical Radiation Oncology. 2014; 4:27-34.
    View on PubMed
  20. ACR Appropriateness Criteria high-dose-rate brachytherapy for prostate cancer. Brachytherapy. 2014 Jan-Feb; 13(1):27-31.
    View on PubMed

Go to UCSF Profiles, powered by CTSI